Medication adherence changes following value-based insurance design

American Journal of Managed Care

Volumn 18, Issue 5, 2012, Pages 265-274

  Farley, Joel F ^a   Wansink, Daryl ^b   Lindquist, Jennifer H ^c   Parker, John C ^b   Maciejewski, Matthew L ^c,d  

^a University of North Carolina   (United States)

^b Blue Cross Blue Shield of North Carolina   (United States)

^c Center for Health Services Research in Primary Care   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; THIAZIDE DIURETIC AGENT;

ARTICLE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; FEMALE; HEALTH PROGRAM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSURANCE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; VALUE BASED INSURANCE DESIGN;

CHRONIC DISEASE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; MEDICATION ADHERENCE; NORTH CAROLINA; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84864396536     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Krueger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther. 2005;22(4):313-356. (Pubitemid 43003324)
2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. (Pubitemid 41127293)
3. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598-1605.
4. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177-186. (Pubitemid 46089734)
5. Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for costrelated medication nonadherence: a review of the literature. J Gen Intern Med. 2007;22(6):864-871. (Pubitemid 46763978)
6. Madden JM, Graves AJ, Ross-Degnan D, Briesacher BA, Soumerai SB. Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007. JAMA. 2009;302(16):1755-1756.
7. Soumerai SB, Pierre-Jacques M, Zhang F, et al. Cost-related medication nonadherence among elderly and disabled medicare beneficiaries: a national survey 1 year before the medicare drug benefit. Arch Intern Med. 2006;166(17):1829-1835. (Pubitemid 44455164)
8. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350. (Pubitemid 38656301)
9. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12(1):21-28. (Pubitemid 43139537)
10. Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7(9):861-867. (Pubitemid 32904146)
11. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26(2):w195-w203.
12. Choudhry NK, Fischer MA, Avorn J, et al. At Pitney Bowes, valuebased insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010;29(11):1995-2001.
13. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29(11):2002-2008.
14. Gibson TB, Mahoney J, Ranghell K, Cherney BJ, McElwee N. Valuebased insurance plus disease management increased medication use and produced savings. Health Aff (Millwood). 2011;30(1):100-108.
15. Gibson TB, Wang S, Kelly E, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff (Millwood). 2011;30(1): 109-117.
16. Fairman KA, Curtiss FR. Making the world safe for evidence-based policy: let's slay the biases in research on value-based insurance design. J Manag Care Pharm. 2008;14(2):198-204. (Pubitemid 351447684)
17. Fairman KA, Curtiss FR. What do we really know about VBID? quality of the evidence and ethical considerations for health plan sponsors. J Manag Care Pharm. 2011;17(2):156-174.
18. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9):2149-2153. (Pubitemid 39167177)
19. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530. (Pubitemid 40847288)
20. Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother. 2009;43(3):413-422.
21. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata J. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27(12):2800-2805. (Pubitemid 39565040)
22. Chernew ME, Juster IA, Shah M, et al. Evidence that value-based insurance can be effective. Health Aff (Millwood). 2010;29(3): 530-536.